---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-049529"
form_type: "8-K"
ticker: "NRXP"
cik: "0001719406"
company_name: "NRX Pharmaceuticals, Inc."
filed_at: "2024-04-19T23:59:59+00:00"
generated_at: "2026-06-03T16:15:07.286755+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# NRx Pharmaceuticals prices $2.0M public offering of common stock at $3.30 per share

## Summary
- Underwritten public offering of 607,000 shares at $3.30/share; gross proceeds ~$2.0M before expenses.
- Underwriters granted 45-day option for up to 91,050 additional shares at same price to cover over-allotments.
- Company will issue to representative EF Hutton a warrant to purchase up to 30,350 shares (5% of shares sold) at $3.63/share.
- Net proceeds to be used for working capital, general corporate purposes, and potential repayment of Streeterville Capital note.
- Offering closed on April 19, 2024; shares sold under existing effective shelf registration statement.

## SEC filing metadata
- accession: 0001104659-24-049529
- form_type: 8-K
- ticker: NRXP
- cik: 0001719406
- company_name: NRX Pharmaceuticals, Inc.
- filed_at: 2024-04-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719406/000110465924049529/0001104659-24-049529-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719406/000110465924049529/tm2412274d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-049529
- JSON: https://secwatch.observer/filing/0001104659-24-049529.json
- Plain text: https://secwatch.observer/filing/0001104659-24-049529.txt

## Key facts
- Material Agreements
  NRX Pharmaceuticals, Inc. entered into Underwriting Agreement with EF Hutton LLC valued at approximately $2.0 million (effective 2024-04-18).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: EF Hutton LLC
  - Value: approximately $2.0 million
  - Effective: 2024-04-18
  source text: On April 18, 2024, NRx Pharmaceuticals, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with EF Hutton LLC (the “ Representative ”), as the representative of the several underwriters named therein (the “ Underwriters ”), relating to an underwritten public offering (the “ Offering ”) of 607,000 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (“ Common Stock ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1719406/000110465924049529/0001104659-24-049529-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.